GB2450770A - Method for enhancing sperm survival using Hsc70 - Google Patents
Method for enhancing sperm survival using Hsc70 Download PDFInfo
- Publication number
- GB2450770A GB2450770A GB0805134A GB0805134A GB2450770A GB 2450770 A GB2450770 A GB 2450770A GB 0805134 A GB0805134 A GB 0805134A GB 0805134 A GB0805134 A GB 0805134A GB 2450770 A GB2450770 A GB 2450770A
- Authority
- GB
- United Kingdom
- Prior art keywords
- spermatozoa
- hsc7o
- protein
- diluent
- viability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 title abstract description 8
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 title abstract description 8
- 230000004083 survival effect Effects 0.000 title description 18
- 230000002708 enhancing effect Effects 0.000 title description 3
- 230000035899 viability Effects 0.000 claims abstract description 76
- 239000003085 diluting agent Substances 0.000 claims abstract description 48
- 239000012528 membrane Substances 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 28
- 241000282326 Felis catus Species 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract description 14
- 241000282836 Camelus dromedarius Species 0.000 claims abstract description 12
- 241000282414 Homo sapiens Species 0.000 claims abstract description 11
- 241001494479 Pecora Species 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 8
- 241000283073 Equus caballus Species 0.000 claims abstract description 7
- 241000406668 Loxodonta cyclotis Species 0.000 claims abstract description 7
- 235000002198 Annona diversifolia Nutrition 0.000 claims abstract description 6
- 241000282842 Lama glama Species 0.000 claims abstract description 6
- 241000282852 Lama guanicoe Species 0.000 claims abstract description 6
- 241000009328 Perro Species 0.000 claims abstract description 6
- 108010039918 Polylysine Proteins 0.000 claims abstract description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 6
- 241001416177 Vicugna pacos Species 0.000 claims abstract description 6
- 241000282840 Vicugna vicugna Species 0.000 claims abstract description 6
- 238000005138 cryopreservation Methods 0.000 claims abstract description 6
- 229920000656 polylysine Polymers 0.000 claims abstract description 6
- 244000144977 poultry Species 0.000 claims abstract description 6
- 229920002307 Dextran Polymers 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229910001868 water Inorganic materials 0.000 claims abstract description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001412 amines Chemical class 0.000 claims abstract description 4
- 239000000661 sodium alginate Substances 0.000 claims abstract description 4
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 4
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000001103 potassium chloride Substances 0.000 claims abstract description 3
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 154
- 102000004169 proteins and genes Human genes 0.000 claims description 153
- 229920000642 polymer Polymers 0.000 claims description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 238000003744 In vitro fertilisation Methods 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 2
- 230000004720 fertilization Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 128
- 239000002609 medium Substances 0.000 description 25
- 210000000582 semen Anatomy 0.000 description 24
- 210000003101 oviduct Anatomy 0.000 description 22
- 241000894007 species Species 0.000 description 21
- 241000283690 Bos taurus Species 0.000 description 18
- 210000002919 epithelial cell Anatomy 0.000 description 18
- 238000011534 incubation Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000004606 Fillers/Extenders Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 210000000287 oocyte Anatomy 0.000 description 11
- 239000000499 gel Substances 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 8
- 244000309464 bull Species 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 102000018697 Membrane Proteins Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 230000003325 follicular Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000000938 luteal effect Effects 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000009027 insemination Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- 108090000279 Peptidyltransferases Proteins 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 108010092854 aspartyllysine Proteins 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000003780 Clusterin Human genes 0.000 description 3
- 108090000197 Clusterin Proteins 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 210000001771 cumulus cell Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 108091005706 peripheral membrane proteins Proteins 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 241000283726 Bison Species 0.000 description 2
- 241000030939 Bubalus bubalis Species 0.000 description 2
- 241000282828 Camelus bactrianus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000282323 Felidae Species 0.000 description 2
- FYYSIASRLDJUNP-WHFBIAKZSA-N Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FYYSIASRLDJUNP-WHFBIAKZSA-N 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VSJAPSMRFYUOKS-IUCAKERBSA-N Met-Pro-Gly Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O VSJAPSMRFYUOKS-IUCAKERBSA-N 0.000 description 2
- 102000005431 Molecular Chaperones Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- SQBLRDDJTUJDMV-ACZMJKKPSA-N Ser-Glu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQBLRDDJTUJDMV-ACZMJKKPSA-N 0.000 description 2
- 241000283968 Syncerus caffer Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 108010005233 alanylglutamic acid Proteins 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000005002 female reproductive tract Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108010003700 lysyl aspartic acid Proteins 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000008010 sperm capacitation Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
- GFBLJMHGHAXGNY-ZLUOBGJFSA-N Ala-Asn-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O GFBLJMHGHAXGNY-ZLUOBGJFSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- CXISPYVYMQWFLE-VKHMYHEASA-N Ala-Gly Chemical compound C[C@H]([NH3+])C(=O)NCC([O-])=O CXISPYVYMQWFLE-VKHMYHEASA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 1
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 1
- JNJHNBXBGNJESC-KKXDTOCCSA-N Ala-Tyr-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JNJHNBXBGNJESC-KKXDTOCCSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- ITVINTQUZMQWJR-QXEWZRGKSA-N Arg-Asn-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O ITVINTQUZMQWJR-QXEWZRGKSA-N 0.000 description 1
- SQKPKIJVWHAWNF-DCAQKATOSA-N Arg-Asp-Lys Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O SQKPKIJVWHAWNF-DCAQKATOSA-N 0.000 description 1
- KRQSPVKUISQQFS-FJXKBIBVSA-N Arg-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N KRQSPVKUISQQFS-FJXKBIBVSA-N 0.000 description 1
- DIIGDGJKTMLQQW-IHRRRGAJSA-N Arg-Lys-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)N DIIGDGJKTMLQQW-IHRRRGAJSA-N 0.000 description 1
- ROWCTNFEMKOIFQ-YUMQZZPRSA-N Arg-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N ROWCTNFEMKOIFQ-YUMQZZPRSA-N 0.000 description 1
- DPLFNLDACGGBAK-KKUMJFAQSA-N Arg-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N DPLFNLDACGGBAK-KKUMJFAQSA-N 0.000 description 1
- FVBZXNSRIDVYJS-AVGNSLFASA-N Arg-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N FVBZXNSRIDVYJS-AVGNSLFASA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- GOVUDFOGXOONFT-VEVYYDQMSA-N Asn-Arg-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GOVUDFOGXOONFT-VEVYYDQMSA-N 0.000 description 1
- BHQQRVARKXWXPP-ACZMJKKPSA-N Asn-Asp-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N BHQQRVARKXWXPP-ACZMJKKPSA-N 0.000 description 1
- VYLVOMUVLMGCRF-ZLUOBGJFSA-N Asn-Asp-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O VYLVOMUVLMGCRF-ZLUOBGJFSA-N 0.000 description 1
- BKDDABUWNKGZCK-XHNCKOQMSA-N Asn-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O BKDDABUWNKGZCK-XHNCKOQMSA-N 0.000 description 1
- YRTOMUMWSTUQAX-FXQIFTODSA-N Asn-Pro-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O YRTOMUMWSTUQAX-FXQIFTODSA-N 0.000 description 1
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 1
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
- KDFQZBWWPYQBEN-ZLUOBGJFSA-N Asp-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N KDFQZBWWPYQBEN-ZLUOBGJFSA-N 0.000 description 1
- VGRHZPNRCLAHQA-IMJSIDKUSA-N Asp-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O VGRHZPNRCLAHQA-IMJSIDKUSA-N 0.000 description 1
- CASGONAXMZPHCK-FXQIFTODSA-N Asp-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)N)CN=C(N)N CASGONAXMZPHCK-FXQIFTODSA-N 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- KHBLRHKVXICFMY-GUBZILKMSA-N Asp-Glu-Lys Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O KHBLRHKVXICFMY-GUBZILKMSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- HKEZZWQWXWGASX-KKUMJFAQSA-N Asp-Leu-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 HKEZZWQWXWGASX-KKUMJFAQSA-N 0.000 description 1
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- NONWUQAWAANERO-BZSNNMDCSA-N Asp-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 NONWUQAWAANERO-BZSNNMDCSA-N 0.000 description 1
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 1
- XAPPCWUWHNWCPQ-PBCZWWQYSA-N Asp-Thr-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XAPPCWUWHNWCPQ-PBCZWWQYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- KLLFLHBKSJAUMZ-ACZMJKKPSA-N Cys-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N KLLFLHBKSJAUMZ-ACZMJKKPSA-N 0.000 description 1
- SBMGKDLRJLYZCU-BIIVOSGPSA-N Cys-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CS)N)C(=O)O SBMGKDLRJLYZCU-BIIVOSGPSA-N 0.000 description 1
- AZDQAZRURQMSQD-XPUUQOCRSA-N Cys-Val-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AZDQAZRURQMSQD-XPUUQOCRSA-N 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001076388 Fimbria Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- ZIYGTCDTJJCDDP-JYJNAYRXSA-N Glu-Phe-Lys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZIYGTCDTJJCDDP-JYJNAYRXSA-N 0.000 description 1
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- KQDMENMTYNBWMR-WHFBIAKZSA-N Gly-Asp-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O KQDMENMTYNBWMR-WHFBIAKZSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- LXTRSHQLGYINON-DTWKUNHWSA-N Gly-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN LXTRSHQLGYINON-DTWKUNHWSA-N 0.000 description 1
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- MUGLKCQHTUFLGF-WPRPVWTQSA-N Gly-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CN MUGLKCQHTUFLGF-WPRPVWTQSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- REPPKAMYTOJTFC-DCAQKATOSA-N Leu-Arg-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O REPPKAMYTOJTFC-DCAQKATOSA-N 0.000 description 1
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 1
- WUFYAPWIHCUMLL-CIUDSAMLSA-N Leu-Asn-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O WUFYAPWIHCUMLL-CIUDSAMLSA-N 0.000 description 1
- POJPZSMTTMLSTG-SRVKXCTJSA-N Leu-Asn-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N POJPZSMTTMLSTG-SRVKXCTJSA-N 0.000 description 1
- TWQIYNGNYNJUFM-NHCYSSNCSA-N Leu-Asn-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O TWQIYNGNYNJUFM-NHCYSSNCSA-N 0.000 description 1
- MMEDVBWCMGRKKC-GARJFASQSA-N Leu-Asp-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N MMEDVBWCMGRKKC-GARJFASQSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 1
- PDQDCFBVYXEFSD-SRVKXCTJSA-N Leu-Leu-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O PDQDCFBVYXEFSD-SRVKXCTJSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- WXJKFRMKJORORD-DCAQKATOSA-N Lys-Arg-Ala Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCCCN WXJKFRMKJORORD-DCAQKATOSA-N 0.000 description 1
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
- JPNRPAJITHRXRH-BQBZGAKWSA-N Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O JPNRPAJITHRXRH-BQBZGAKWSA-N 0.000 description 1
- ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 1
- PBIPLDMFHAICIP-DCAQKATOSA-N Lys-Glu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PBIPLDMFHAICIP-DCAQKATOSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 1
- CTBMEDOQJFGNMI-IHPCNDPISA-N Lys-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CCCCN)N CTBMEDOQJFGNMI-IHPCNDPISA-N 0.000 description 1
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 1
- MUXNCRWTWBMNHX-SRVKXCTJSA-N Lys-Leu-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O MUXNCRWTWBMNHX-SRVKXCTJSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- VUTWYNQUSJWBHO-BZSNNMDCSA-N Lys-Leu-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O VUTWYNQUSJWBHO-BZSNNMDCSA-N 0.000 description 1
- ALGGDNMLQNFVIZ-SRVKXCTJSA-N Lys-Lys-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ALGGDNMLQNFVIZ-SRVKXCTJSA-N 0.000 description 1
- ZJSZPXISKMDJKQ-JYJNAYRXSA-N Lys-Phe-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 ZJSZPXISKMDJKQ-JYJNAYRXSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 1
- WINFHLHJTRGLCV-BZSNNMDCSA-N Lys-Tyr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=C(O)C=C1 WINFHLHJTRGLCV-BZSNNMDCSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- DSZFTPCSFVWMKP-DCAQKATOSA-N Met-Ser-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN DSZFTPCSFVWMKP-DCAQKATOSA-N 0.000 description 1
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 1
- VWFHWJGVLVZVIS-QXEWZRGKSA-N Met-Val-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O VWFHWJGVLVZVIS-QXEWZRGKSA-N 0.000 description 1
- QAVZUKIPOMBLMC-AVGNSLFASA-N Met-Val-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(C)C QAVZUKIPOMBLMC-AVGNSLFASA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282372 Panthera onca Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- LNIIRLODKOWQIY-IHRRRGAJSA-N Phe-Asn-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O LNIIRLODKOWQIY-IHRRRGAJSA-N 0.000 description 1
- LDSOBEJVGGVWGD-DLOVCJGASA-N Phe-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 LDSOBEJVGGVWGD-DLOVCJGASA-N 0.000 description 1
- ZENDEDYRYVHBEG-SRVKXCTJSA-N Phe-Asp-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 ZENDEDYRYVHBEG-SRVKXCTJSA-N 0.000 description 1
- RIYZXJVARWJLKS-KKUMJFAQSA-N Phe-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RIYZXJVARWJLKS-KKUMJFAQSA-N 0.000 description 1
- FRPVPGRXUKFEQE-YDHLFZDLSA-N Phe-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O FRPVPGRXUKFEQE-YDHLFZDLSA-N 0.000 description 1
- LWPMGKSZPKFKJD-DZKIICNBSA-N Phe-Glu-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O LWPMGKSZPKFKJD-DZKIICNBSA-N 0.000 description 1
- VZFPYFRVHMSSNA-JURCDPSOSA-N Phe-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 VZFPYFRVHMSSNA-JURCDPSOSA-N 0.000 description 1
- OWSLLRKCHLTUND-BZSNNMDCSA-N Phe-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)N)C(=O)O)N OWSLLRKCHLTUND-BZSNNMDCSA-N 0.000 description 1
- RAGOJJCBGXARPO-XVSYOHENSA-N Phe-Thr-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 RAGOJJCBGXARPO-XVSYOHENSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 1
- HAEGAELAYWSUNC-WPRPVWTQSA-N Pro-Gly-Val Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O HAEGAELAYWSUNC-WPRPVWTQSA-N 0.000 description 1
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 description 1
- DSGSTPRKNYHGCL-JYJNAYRXSA-N Pro-Phe-Met Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(O)=O DSGSTPRKNYHGCL-JYJNAYRXSA-N 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- GVUVRRPYYDHHGK-VQVTYTSYSA-N Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 GVUVRRPYYDHHGK-VQVTYTSYSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 1
- DBIDZNUXSLXVRG-FXQIFTODSA-N Ser-Asp-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N DBIDZNUXSLXVRG-FXQIFTODSA-N 0.000 description 1
- ZKBKUWQVDWWSRI-BZSNNMDCSA-N Ser-Phe-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZKBKUWQVDWWSRI-BZSNNMDCSA-N 0.000 description 1
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 description 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- RXUOAOOZIWABBW-XGEHTFHBSA-N Ser-Thr-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RXUOAOOZIWABBW-XGEHTFHBSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IGROJMCBGRFRGI-YTLHQDLWSA-N Thr-Ala-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O IGROJMCBGRFRGI-YTLHQDLWSA-N 0.000 description 1
- FQPQPTHMHZKGFM-XQXXSGGOSA-N Thr-Ala-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O FQPQPTHMHZKGFM-XQXXSGGOSA-N 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- CAGTXGDOIFXLPC-KZVJFYERSA-N Thr-Arg-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CCCN=C(N)N CAGTXGDOIFXLPC-KZVJFYERSA-N 0.000 description 1
- SWIKDOUVROTZCW-GCJQMDKQSA-N Thr-Asn-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C)C(=O)O)N)O SWIKDOUVROTZCW-GCJQMDKQSA-N 0.000 description 1
- YLXAMFZYJTZXFH-OLHMAJIHSA-N Thr-Asn-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O YLXAMFZYJTZXFH-OLHMAJIHSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- DCRHJDRLCFMEBI-RHYQMDGZSA-N Thr-Lys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O DCRHJDRLCFMEBI-RHYQMDGZSA-N 0.000 description 1
- MXNAOGFNFNKUPD-JHYOHUSXSA-N Thr-Phe-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MXNAOGFNFNKUPD-JHYOHUSXSA-N 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- CYCGARJWIQWPQM-YJRXYDGGSA-N Thr-Tyr-Ser Chemical compound C[C@@H](O)[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CO)C([O-])=O)CC1=CC=C(O)C=C1 CYCGARJWIQWPQM-YJRXYDGGSA-N 0.000 description 1
- QNXZCKMXHPULME-ZNSHCXBVSA-N Thr-Val-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O QNXZCKMXHPULME-ZNSHCXBVSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 1
- DWAMXBFJNZIHMC-KBPBESRZSA-N Tyr-Leu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O DWAMXBFJNZIHMC-KBPBESRZSA-N 0.000 description 1
- RGJZPXFZIUUQDN-BPNCWPANSA-N Tyr-Val-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O RGJZPXFZIUUQDN-BPNCWPANSA-N 0.000 description 1
- WGHVMKFREWGCGR-SRVKXCTJSA-N Val-Arg-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WGHVMKFREWGCGR-SRVKXCTJSA-N 0.000 description 1
- PMXBARDFIAPBGK-DZKIICNBSA-N Val-Glu-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PMXBARDFIAPBGK-DZKIICNBSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- OTJMMKPMLUNTQT-AVGNSLFASA-N Val-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N OTJMMKPMLUNTQT-AVGNSLFASA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010080488 arginyl-arginyl-leucine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 108010073093 leucyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010045397 lysyl-tyrosyl-lysine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000010844 nanoflow liquid chromatography Methods 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010093296 prolyl-prolyl-alanine Proteins 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 101150093914 seqA gene Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/07—Heat shock proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
A spermatozoa diluent comprising isolated Hsc70 protein, in which the Hsc70 has sperm viability improving and/or prolonging activity. The Hsc70 may be in the range 0.1ug/L to 10g/L, and may be selected from human, pig, sheep, ox, camel, horse, dog, cat, poultry, rabbit, buffalo, elephant, llama, guanaco, alpaca and vicuna. Preferably the Hsc70 comprises the sequence SEQ ID NO:1, and may also be linked to an inert hydrophilic polymer (amine and carbonyl-reactive dextran). The diluent may also comprise at least one of: glucose, socium citrate dehydrate, EDTA, sodium bicarbonate, potassium chloride, or water; and may also comprise spermatozoa, which may be microencapsulated in sodium alginate gel or in a semi-permeable membrane comprising poly-lysine. Also claimed are: a kit of parts; manufacture of a medicament; method of improving/prolonging sperm viability which may include cryopreservation, sex-sorting, or be part of in vitro fertilization.
Description
Method for enhancing sperm survival This invention relates to
maintenance of sperm viability to increase the success rate of artificial insemination (A!). Al is when spermatozoa are introduced into a female's reproductive tract using artificial means rather than by natural copulation.
A! is used in animals to propagate desirable characteristics of one male to one or more females or to overcome breeding problems. A! is now a fundamental technology for the intensive breeding of domestic animals, in human infertility treatments and in wildlife conservation programmes for the breeding of threatened species. Nevertheless, it has become clear that current semen preservation techniques severely compromise the spermatozoa's survival in the female reproductive tract and hence limit the successful application of the technique.
Sperm survival is particularly compromised when spermatozoa cannot be delivered directly into the uterus because the cervical anatomy is too complex, for example in * *. sheep. This significantly reduces the efficiency of A!. Large numbers of viable spermatozoa must be used to maximize the chance of fertilization, therefore making this technique uneconomical. Surgical intrauterine insemination by laparoscopy is an efficient way of solving this problem and through use of this method conception rates of *. better than 60% are now common in sheep and other species. However, this method is * increasingly regarded as unacceptable for routine agriculturaJ use on grounds of welfare; in some countries routine use of this surgical approach is expected to be curtailed within ***.** * a relatively short period.
Means to improve the success rate of non-surgical methods is therefore urgently required. One means of achieving this is by extending the lifespan of spermatozoa in the female reproductive tract.
Following mating (natural insemination), inseminated mammalian spermatozoa are transported to the oviduct where a reservoir of spermatozoa is formed. Studies in several species have shown that the reservoir is limited to the caudal isthmus. The spermatozoa are held in the isthmus until ovulation, when a small number are released to meet the P2988RVC0803 I 8j egg(s). During storage in the isthmus, many spermatozoa attach to the oviductal epithelial cells. Attachment to oviductal epithelial cells is important in maintaining sperm viability both in viva and in vitro. Sperm attachment to oviductal epithelial cells is initiated by uncapacitated spermatozoa. The process of capacitation, along with the switch to the hyperactivated fiagellar beating pattern, appears to coincide with the ability of spermatozoa to be released from the oviductal reservoir.
Co-culture of spermatozoa with whole oviductal epithelial cells in vitro improves the viability of spermatozoa from a number of species including rabbit, ox, sheep, horse, pig and human. It seems this is a widespread characteristic of oviductal cells however the mechanism by which oviductal cells maintain sperm viability is unknown. Both oviductal secretory products and direct membrane contact between spermatozoa and oviductal epithelial cell membranes have been reported to bestow this beneficial effect.
Despite the importance of direct membrane contact between oviduct epithelia and spermatozoa, and the possible involvement of oviductal membrane proteins in this interaction, many studies in the past have only investigated the role of oviductal secretory products (proteins) on spermatozoa. This was related to the ease of obtaining oviduct secretory products from in vivo, and the fact that exposure to an epithelial :: : :* 20 membrane fraction invariably exposed spermatozoa to secretory proteins at the same * time. The development of a membrane fractionation protocol (Smith and Nothnick, * 1997) facilitated the investigation of the role of apical plasma membranes (MM) in improving sperm viability by providing the first in vitro model for studying interactions S.....
* S between spermatozoa and oviductal MM without the interference of oviduct secretions.
US 7,070,918, (herein incorporated by reference in its entirety) discloses that the soluble apical plasma membrane (sAPM) fraction of oviductal epithelial cells is associated with the maintaining/improving/prolonging activity of sperm viability.
In a study carried out to investigate normal and polyspermic fertilization rates of spermatozoa exposed to oviductal epithelial APM proteins (Satake et aL), proteins were extracted and solubilised from the APM of the oviduct, prior to co-culture with oocytes in in vitro fertilisatjon (IVF). The overall fertilization rate was significantly higher (78% P2988RVC0803 183 vs. 86%) when spermatozoa were incubated in the presence of APM proteins (P <0.05).
Moreover, polyspermic fertilisation was significantly reduced (47% vs. 21%) when spermatozoa were exposed to APM proteins (P <0.01). The results of this study suggest that exposure of spermatozoa to APM proteins prior to P/F increases fertilization rate and decreases the incidence of polyspermic penetration.
Thus, the APM of oviductal epithelial cells appears to contain one or more factors which can not only prolong/improve sperm viability, but also increase rates of fertilisation in P/F (and reduce polyspermic fertilisation).
Further experimental methodology has been developed and utilised by the present inventors to identify one or more candidate proteins within sAPM which are responsible for the maintaining/improving/prolonging activity of sperm viability. The inventors have now identified a molecular chaperone, Hsc7O, which is present within the sAPM of oviductal epithelial cells, and which possesses the ability to maintain and/or improve and/or prolong the viability of spermatozoa. S S. * . .
According to a first aspect of the present invention, there is provided a spermatozoa diluent comprising isolated Hsc7O protein, in which the Hsc7O has sperm viability :*:. 20 improving and/or prolonging activity. * S..
S
* "Diluent" in this context includes any liquid or solid material used to dilute and/or carry the spermatozoa.
S'S... * .
"Isolated" means a protein, which is substantially free of other cellular proteins found with that protein in nature.
"Hsc7O" includes whole Hsc7O protein, or one or more fragments, domains, or peptides derived from Hsc7O which retain the ability to improve and/or prolong sperm viability.
By "viability improving activity" is meant an ability to increase the proportion of spermatozoa which are viable in comparison with control spermatozoa.
P2988RVC0803 18j By "viability prolonging activity" is meant an ability to maintain the viability of spermatozoa for a longer time period than the normal lifespan of control spermatozoa which are not contacted with the Hsc7O protein. This longer time period preferably extends for from one day to three days, or greater than three days.
Molecular chaperones are ubiquitous proteins, the major classes of which include the six families of heat-shock proteins (Hsps). These proteins, so named because temperature elevation (heat shock) was the first described inducer of the response, have been found in virtually all organisms and are highly conserved phylogenetically. The Hsps most involved in protein folding are members of the Hsp4O, Hsp6O and Hsp7O families. Each Hsp gene family comprises different forms of the protein; for example, most organisms have around 12 isoforms of the 7OkDa Hsp family, with members found in various cellular compartments, and having different expression patterns. Some isoforms are constitutively expressed (e.g. Hsc7O) and others are stress-induced (e.g. Hsp7O). I5
There is provided a spermatozoa diluent comprising HsclO protein, in which the Hsc7O *:*::* has sperm viability improving and/or prolonging activity. * * * ***
The concentration of the Hsc70 protein may be between approximately 0.1 g/L and 10 g/L. *
* * * Preferably, the spennatozoa diluent or additive is synthetic. By synthetic we mean the diluent or additive is synthesised de novo. The advantage of synthetic diluents or ****** * additives is that these substantially eliminate the risk of transmitting viruses or other contaminants which might be associated with products obtained directly from mammalian tissue.
There is provided a spermatozoa diluent comprising Hsc7O protein, in which the Hsc70 has sperm viability improving and/or prolonging activity, wherein the concentration of the Hsc7O protein is between approximately 0.1 j.tg/L and 10 g/L.
The concentration of the Hsc7O protein in the diluent may be between approximately 0.1 g/L to 10 g/L, or between 1 j.tg/L to 1 g/L, or between 10 gfL to 500 mg/L, or between P2988RVC0803 18j 10.tg/L to 200 mgfL, or between 100 j.tg/L to 200 mgIL, or between 200 g/L to 200 mg/L, or between 500 pg/L to 200 mg/L, or between 500 j.tg/L to 100 mgfL.
Preferably a concentration of between approximately 0.05 mgfL and approximately 10 mg/L is used. More preferably a concentration of between approximately 0.1 mgfL and approximately 5 mg/L is used. More preferably still, the concentration used is between approximately 1 mg/L and approximately 4 mg/L. Optimally, the concentration of the Hsc7O protein in the diluent is about I mg/L (or 1 j.tg/ml), or about 2 mgfL (or 2 g'ml), or about 3 mg/L (or 3 p.g/ml), or about 4 mg/L (or 4 j.tg/ml).
The HsclO protein may be contained within a membrane fraction or membranes, which may be from oviductal epithelial cells. The Hsc7O may be contained within an apical membrane fraction. The membrane fraction may be soluble or insoluble. The membrane fraction may be enriched for Hsc7O, i.e. contain a greater concentration of Hsc7O than is present endogenously in apical membranes of oviductal epithelial cells. The concentration of the Hsc7O protein in the membrane fraction or membranes, or the diluent may be between approximately 0.1 j.tg(L and 10 g/L. Preferably a concentration of between approximately 5.tg/L and approximately 400.LgfL is used. More preferably S...
the concentration used is between approximately 25 jg(L and approximately 200.tg/L. * S* 20 *...
* The diluent may comprise further additives. The diluent may comprise any mixed salt * *, and/or sugar solution with an isosmolarity similar to or greater than the osmolarity of seminal fluid which is supportive to spenn viability. The diluent may also comprise S.. .** * * additional proteins, peptides or organic molecules, and/or water-soluble polymers and/or cryoprotective agents. The diluent may comprise one or more antibiotics.
The diluent may comprise a semen extender. The diluent may be a semen extender.
Semen extenders are variable in actual ingredients, but all contain ingredients that serve a common purpose, i.e. nourish the spermatozoa, buffer the pH, protect the spermatozoa during temperature change, and kill microorganisms (e.g. bacteria) within the semen.
The semen extender may comprise one or more nutrients, buffers, cryoprotective agents, and/or antibiotics.
P2988RVC080318j The nutrient may be a sugar, such as glucose or sucrose, which serves to provide energy source for the sperm. Buffers are added to balance pH and osmolarity of the solution, and the sugars may also serve this purpose. The cryoprotective agent may be glycerol or DMSO. The extender may comprise egg yolk, which is a common ingredient in a wide variety of frozen semen extenders.
The diluent or extender may be Beltsville Thawing Solution. The diluent may comprise one or more of glucose, sodium citrate dihydrate, EDTA, sodium bicarbonate, potassium chloride, and water. l0
Other diluents and extenders are commercially available and will be well known to a person skilled in the art of Al.
In another aspect the Hsc7O protein may comprise the sequence of SEQ ID NO: I. The Hsc7O protein may have at least 80% identity with the protein listed in SEQ ID NO.
1, or at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identity with the protein listed in SEQ ID NO. 1. * ** * 20
* * The Hsc7O protein may be from any animal which is propagated by Al. * **
The Hsc7O protein may be selected from the group consisting of: human, pig, sheep, ox, * camel, horse, dog, cat, poultry, rabbit, buffalo, elephant, llama, guanaco, alpaca, and vicuna.
The cat may be any cat contained within the family Felidae, and may therefore include members of the Panthera genus such as lion, tiger, leopard, and jaguar. The cat may be a domestic cat.
The camel may be a Bactrian camel, a Dromedary camel, or a hybrid camel.
P2988RVC0803 1 8j The buffalo may be a bison, a water buffalo (also known as Swamp Buffalo and Indian Buffalo), or a Cape buffalo.
The Hsc7O protein may be bovine Hsc7O.
The Hsc7O protein may be isolated and/or purified from an animal or human source, or it may be produced using recombinant DNA technology, or synthesised chemically. Such techniques are well established and will be known to a person skilled in the art.
The Hsc7O protein may be linked to an inert polymer. By "linked" it is meant that the polymers are joined to the protein; the join may be through one or more ionic or covalent bonds. Such linking is well known in the art and can result in the advantages of increased efficiency and reduced toxicity.
The polymer may be hydrophilic. Hydrophilic polymers are defined as polymers having a solubility of greater than 1 Og/L in an aqueous solution, at a temperature between 0 to deg C. The aqueous solution may include small amounts of water-soluble organic solvents, such as dimethylsulfoxide, dimethylfonnamide, alcohols or acetone. The * *** polymer may be polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, :.:::. 20 hydroxylated celluloses, polypeptides, polysacchandes such as polysucrose or dextran * and alginate. * **
The polymer may be amine and carbonyl-reactive dextran. *S..* * *
The concentration of Hsc7O protein in the diluent may be equal to or greater than the concentration of membrane bound Hsc7O in oviductal epithelial cells. The concentration of Hsc7O protein in the diluent may be equal to or greater than the total concentration of Hsc7O contained within oviductal epithelial cells.
The diluent may further comprise spermatozoa.
P2988RVC0803 I 8j The spermatozoa may be selected from the group consisting of: human, pig, sheep, ox, camel, horse, dog, cat, poultry, rabbit, buffalo, elephant, llama, guanaco, alpaca, and vicuna.
The camel may be a Bactrian camel, a Dromedary camel, or a hybrid camel.
The buffalo may be a bison, a water buffalo, or a Cape buffalo.
The cat may be any cat contained within the family Felidae. The cat may be a domestic cat.
The conservation within HsclO proteins across different species means that Hsc7O protein from one species may be used to improve/prolong sperm viability for another species, whether closely related, or distantly related. The Hsc7O protein may be from one species, and the spermatozoa may be from a different species. The Hsc7O protein and the spermatozoa may be from the same species, or from species within the same genus, or *:::* sub-family, or family, or order, or class, or phylum. S... * S S...
The Hsc7O protein may be bovine Hsc7O and the spermatozoa may be porcine, ovine or :.:... 20 bovine spermatozoa. * S..
I
: ** The spermatozoa may be microencapsulated. By "microencapsulated", is meant that the spermatozoa are enclosed within a semi-permeable membrane. Examples of membranes **....
* which can be used include beeswax, starch, gelatine, and polyacrylic acid and polylysine.
The spermatozoa may be microencapsulated in a semi-permeable membrane. The semi-permeable membrane may comprise poly-lysine.
The spermatozoa may be microencapsulated in a gel, which may be a sodium alginate gel.
According to a further aspect of the present invention, there is provided a kit of parts comprising the diluent of the first aspect of the invention, and spermatozoa.
P2988RVC0803 I 8j According to a further aspect of the present invention, there is provided a composition comprising spermatozoa and Hsc7O protein.
According to a further aspect of the present invention, there is provided a use of the diluent of the first aspect of the invention to improve and/or prolong sperm viability.
According to a further aspect of the present invention, there is provided a use of Hsc7O protein to improve and/or prolong spermatozoa viability.
The use may be carried out in vivo or in vitro.
According to a further aspect of the present invention, there is provided a use of Hsc7O protein in the manufacture of a medicament to improve and/or prolong sperm viability.
According to a further aspect of the present invention, there is provided a use of Hsc7O in the artificial insemination of a human or animal. * ** **.. * . *..*
According to a further aspect of the present invention, there is provided a method of :.:,:* 20 improving and/or prolonging sperm viability which comprises contacting spermatozoa * with HsclO in vitro * ** The method may be performed during in vitro fertilisation. S.. * .
There is provided a method of in vitro fertilisation, comprising contacting spermatozoa with Hsc7O and contacting the spermatozoa with one or more oocytes or IVF droplets comprising one or more oocytes.
According to a further aspect of the present invention, there is provided a method of artificially inseminating an animal, the method comprising contacting spermatozoa with Hsc7O and inseminating the animal.
P2988RVC0803 I 8j Numerous IVF and artificial insemination methodologies exist, and these are considered to be well known to a person skilled in the art.
The spermatozoa may be chilled, frozen or at ambient temperature or body temperature.
The spermatozoa may be stored frozen or at any temperature in the range -9 deg C to 45 deg C. The spermatozoa may be in the vitrified state.
The Hsc7O may be provided in a diluent according to the first aspect of the present invention.
The spermatozoa may be cryopreserved prior to contact with Hsc7O.
The spermatozoa may be contacted with Hsc7O during cryopreservation.
The method may be carried out before or after sex-sorting of the spermatozoa for X- (female) and Y-bearing (male) spermatozoa. * S. * . S
:.:: A method as claimed in any one of claims 27-30, the Hsc7O and spermatozoa being S...
: contacted for between about 30 seconds and 14 days.
*... 20 * The spermatozoa and Hsc7O may be contacted for between about 30 seconds and 14 * * days, or between about 30 seconds and 12 days, or between about 30 seconds and 10 days, or between about 30 seconds and 8 days, or between about 1 minute and 6 days, or S.....
* between about 1 minute and 3 days, or between about 1 minute and 2 days, or between about 1 minute and 24h, or between about 1 minute and I 2h, or between 1 minute and 6h, or between about 5 minutes and 3h, or between about 10 minutes and lh.
The present invention will be further apparent from the following description, which shows, by way of example only, specific embodiments of the use of Hsc7O and experimentation therewith.
P2988RVC0803 1 8j
Brief description of the figures
Figure 1 shows the viability index (mean SEM) of boar spermatozoa incubated with different concentrations of antibodies; Figure 2 shows the viability index (mean SEM) of boar spermatozoa incubated with s different concentrations of bovine HsclO; Figure 3 shows the viability index (mean SEM) of boar spermatozoa incubated with bovine Hsc7O, oviductal APM proteins, and TALP medium; Figure 4A shows the viability index (mean SEM) of boar spermatozoa incubated for 24 h at 39 C in the presence of soluble apical plasma membrane protein fraction and either anti-hsp7O or anti-hsc7O antibody, Figures 4B and 4C show the viability index (mean SEM) of boar spermatozoa incubated for 24h at 39 C in the presence of TLP, sAPM (2OOtg/mL) or two concentration ranges of recombinant Hsc7O; Figure 5 shows the viability index (mean SEM) of bull spermatozoa incubated for 48h with various concentrations of recombinant bovine Hsc7O; Figure 6 shows the viability index (mean SEM) of ram spermatozoa incubated for 48h * with various concentrations of recombinant bovine Hsc7O; and Figure 7 shows the scores table from a ClustaiW alignment of 33 Hsc7O protein * **.
sequences. * .* * * . "S.
Experimental * ,* Methods and Materials * Oviduct tissue preparation *5SSSS * 5 Porcine oviduct tissues were obtained and oviducts (attached to ovaries) were cleaned and washed with cold PBS. The oviducts were divided into two groups designated: FOL (follicular) and LUT (luteal), based on the appearance of the associated ovaries. Those oviducts attached to ovaries containing large follicles (8-12 mm in diameter) with signs of recent ovulation and no corpora lutea were assigned to the FOL group, those with ovaries containing several corpora lutea, without large follicles were assigned to the LUT group. Oviducts in both groups were trimmed from the ovaries and washed by passing four times through PBS. Each oviduct was divided into three sections; the first, designated as ampulla, was a section between the fimbria and the middle (thicker part) of the oviductal tube. The second section designated as isthmus, consisted of 1-2 cm of the P2988RVC0803 1 8j caudal part of the uterine horn, the uterotubal junction, and up to nearly the middle (thinner part) of the oviductal tube. Finally, a section around the junction of the thin and thick part of the oviductal tube, approximately 2-3 cm long, was excised and discarded to assure differentiation of isthmic and ampullar parts of the oviduct. Each oviduct section (isthmic or ampullar) was processed separately. They were opened longitudinally and epithelia were scraped into a Petri dish using a clean glass microscope slide. Scraped tissues collected from approximately 8-12 oviduct sections were collected separately (FOL isthmus, FOL ampulla, LUT isthmus and LUT ampulla) into 20 ml of cold PBS and kept on ice. These suspensions were centrifuged for five minutes at 200 g. The supernatants were discarded and pellets were resuspended in 20 ml of buffer 1 containing mM mannitol, 5 mM EGTA, I iM phenylmethylsulfonyifluoride (PMSF), Tris base (pH 7.4). Suspensions (5 ml) were snap frozen in liquid nitrogen and stored at -80 deg C. until subsequent use for APM preparation.
sAPM Preparation Tissue homogenates were thawed and homogenized on ice for one minute using a small homogeniser (Silverson, Waterside, UK). Two hundred microlitre aliquots of this initial homogenate were snap-frozen in liquid nitrogen and stored at -80 deg. C. for subsequent * a*.
analyses. The homogenate was supplemented with 2001.il of IM MgCl2 followed by 30 ... 20 minutes incubation on ice. Thereafter the homogenate was centrifuged for 15 minutes at 3000 g. The pellet was discarded and the supernatant was centrifuged for 30 minutes at * ** 90,000g. After centrifugation, the pellet was resuspended in 20 ml of buffer 2 containing mM mannitol, 7 mM EGTA, Tns base (pH 7.4) with ten strokes of a Potter S *.**.
* homogenizer. The homogenate was supplemented with 200 tl 1M MgCI2 and incubated on ice for 30 minutes. Afterwards, the mixture was centrifuged at 3000 g for 15 minutes.
The pellet was discarded and the supematant was centrifuged at 90,000 g for 30 minutes.
The pellet, following ultracentrifi.igation, was resuspended in 20 ml of a modified Tyrode's medium containing 2 mM CaC12, 3.1 mM KC1, 0. 4 mM MgCl2.6H20, 100 mM NaC1, 25 mM NaHCO3, 0.3 j.tM NaH2PO42H2O, 10 mM HEPES, 21.6 mM Sodium lactate and 1 mM sodium pyruvate with ten strokes of a Potter S homogenizer. The suspension was centrifuged for 30 minutes at 90,000 g. The supematant was discarded and the pellet was resuspended in 900 il of the modified Tyrnde's medium by aspiration P2988RVC0803 18j through a 0.9x90 mm Yale spinal needle (Becton Dickinson, Oxford, UK). This fraction was portioned, snap-frozen in liquid nitrogen and stored at -80 deg. C. Protein and [gamma] -glutamyl Transpeptidase Activity Analysis Protein concentrations of initial homogenates, final APM preparations from different tissues, and peripheral membrane protein fractions obtained from oviductal APM, were quantified using a Bio-Rad Protein Assay kit (Bio-Rad, Hemel Hempstead, UK). The kit is based on a dye-binding assay, in which the colour of the dye changes differentially, in response to change in protein concentration. [Ganimaj-glutamyl transpeptidase has previously been shown to reside mainly in the APM of polarized epithelial cells. The activity of [gamma]-glutamyl Iranspeptidase in the initial homogenate and in the APM preparations was measured calorimetrically, using the Sigma diagnostic kit 545 (Sigma, Poole, Dorset, UK). The assay is based on the transfer of the glutamyl group from L-glutamyl-p-nitroanilide to glycyiglycine catalyzed by [gamma]-glutamyl transpeptidase.
The liberated p-nitroaniiine is diazotized by the addition of Sodium Nitrite and Ainmonium Sulfamate. The absorbance of the pink azo- dye resulting from the addition of N-(l-napthyl)-ethylenediamine, measured at 530-550 rim, is proportional to [ganuna]-* *.
glutamyl transpeptidase activity. The degree of enzyme enrichment was expressed as fold increase in [gamma]-glutamyl transpeptidase activity in the final APM preparations 20 compared to the initial homogenate. This demonstrated the success of the method employed to isolate APM preparations from the initial homogenates. In addition, distinct * *, differences in the protein profile of APM preparations were observed compared to that of original homogenates. Three proteins diminished and three were enriched in APM * 1 preparations compared to that of the initial oviductal homogenates.
Semen preparation Boar semen, diluted and stored for 24 hrs in Beltsville thawing solution was obtained, and the semen (45 ml) washed three times with PBS by centrifugation and resuspension (600 g for 10 mm). After the last centrifugation the supernatant was discarded, and the pellet was resuspended in modified Tyrode's medium supplemented with 12 mg/mI BSA (TALP), 200 U/mi penicillin, 200 jig/mI streptomycin and 0.5 jig/mi amphotericin B (Life Technologies, Paisley, UK) (supplemented Tyrode's medium). One ml of washed semen sample was overlaid with 500 jil of supplemented Tyrode's medium in a test tube.
P2988RVC0803 I 8j The tube was placed at a 45 degree angle in an incubator held at 39 deg. C. in a humidified atmosphere saturated with 5% CO2. After one hour the top 0.5 ml of medium containing the swim-up spermatozoa fraction was collected. Spermatozoa concentration was measured using a counting chamber.
Sperm viability was assessed using a combination of Ethidium homodimer-1 (ETHD-1; Molecular Probes, Leiden, The Netherlands) and SYBR-14 (Molecular Probes, Leiden, The Netherlands). One p1 of 2 mM ETHD1 and 2.5 jil of 20 pM SYBR-14 were diluted in I ml of PBS. An equal volume of the dye mixture was added to the semen sample and incubated for 20 minutes at 39 deg. C. An aliquot of this preparation was placed on a slide and evaluated by epifluorescence microscopy (x40 objective). Viable spermatozoa with intact membranes excluding ETHD-l demonstrated green fluorescence over the nucleus due to SYBR-l4 staining. Spermatozoa with disrupted membranes showed red nuclear fluorescence due to ETHD-1 staining. Two hundred spermatozoa were evaluated by fluorescence microscopy and classified as membrane intact (green) or membrane damaged (red). The same methodology was used for the preparation of ram and bull * ** semen. *1 I * ** Is.. * S
* Gel electrophoresis *:.. 20 Gel electrophoresis procedures were carried out using a Bio-Rad Modular Mini Electrophoresis System (Bio-Rad Labs, Hemel Hempstead, Herts, UK) using the * *, discontinuous buffer system (Laemmli, 1970). 5j.tg protein of original homogenate and ** . . .. punfied APM preparations obtained from FOL isthniic, FOL ampullar, LUT isthmic, S.....
* U LUT ampullar and lung tissues were loaded on SDS-polyacrylamide gels (12% separation, 5% stacking). Proteins were fractionated by electrophoresis for between approximately 45 mins to 1 hr at between approximately 180 to 200 volts. Following electrophoresis the gels were fixed and then stained with Brilliant Blue G-Colloidal concentrate (Sigma, Poole, Dorset, UK). A digital image was produced from stained gels using a Hewlett Packard Scanjet 6200c scanner (CA, USA). The image was further analyzed using Scion image Beta 4.0.2 software program (Scion Corporation, MD, USA). Protein profiles of oviduct peripheral membrane proteins, pellet left after the recovery of peripheral membrane proteins, and oviductal APM were produced and analyzed using the methodology described above.
P2988RV2O8O3 1 8j Labelling and detection of sA PM proteins The lumena of sow oviducts were treated with the biotinylation reagent Sulfo-NHS-LC-biotin so that proteins lining the oviduct that would normally come into contact with spermatozoa were labelled. The method for purification and solubilisation of the sAPM was carried out as described above. Semen was washed through a Percoll density gradient and the resulting spermatozoa were incubated with the labelled sAPM.
Unbound sAPM was removed and the membranes of spermatozoa were solubilised in SDS. The mixture was centrifuged to isolate the surface proteins from the spermatozoa and any sAPM proteins that may have bound to them. The proteins were then fractionated by SDS-PAGE, transferred to a nylon membrane by electroblotting, and the biotinylated proteins detected using an Avidin horse-radish peroxidise conjugate, NeutrAvidin/HRP.
Identflcation of candidate sAPM proteins using proteomic analysis Samples of spermatozoa/sAPM were separated by SDS-PAGE and the proteins stained with Coomassie blue. Using a western blot for comparison, stained protein bands of *:*:: interest were cut from the stained gel. Each gel band was diced into approximately 1mm3 . *... 20 pieces and then destained with 200mM ammonium bicarbonate with 40% (v/v) * *. acetonithle. The gel pieces were incubated overnight in a trypsin solution of 0.4 jtg trypsin (Promega, Southampton, UK) and 50 2l of 50mM ammonium bicarbonate. The S..
next day, peptides were extracted in four sequential extraction steps using 30 j.ii of 25mM NH4CO3 (10mm, room temperature), 30 jl acetomtrile (15mm, 37 C), 50.il of 5% (v/v) formic acid (15 mm, 37 C), and finally, with 30 jtl acetonitrile (15 mm, 37 C).
All extracts were pooled and dried in a vacuum centrifuge.
Dried peptides were resuspended in 0.1% (v/v) formic acid in 3% acetonitrile. The mixture was separated on a PepMap C18 RP capillary column (LC-Dionex, Leeds, UK), and eluted in a 60-minute gradient via a LC packings Ultimate nanoLC directly into the mass spectrometer. The compositions of the hydrophilic and hydrophobic solvents were 5% (v/v) acetonitrile, 0.1% (v/v) formic acid and 95% (v/v) acetomtrile, 0.1% (v/v) formic acid. An Applied Biosystems/MDS-Sciex QStarXL electrospray ionisation P2988RVC0803 I Sj quadrapole time-of-flight tandem mass spectrometer (ESI-qQ-TOF) was used for mass spectrometric analysis. Analyst Qs software (Applied Biosystems) was used for data acquisition and data analysis. The data acquisition was perfonned in the positive ion mode using Infonnation dependent Acquisition (IDA). After each TOF-MS scan, three peaks with charge states two or three were selected for tandem mass spectrometry.
The peptide-based protein matches were obtained using MASCOT 2.0 software (www.matrixscience.com). A sequence query search was performed using the Mass Spectrometry protein sequence DataBase (MSDB, Nov 2004). The taxonomy was limited to filter for only mammalian matches, and trypsin was used as enzyme, with one missed cleavage site allowed. The peptide tolerance was set to I.ODa and the MS/MS tolerance was set to 0.25Da.
Hsc7O protein Recombinant bovine Hsc7O protein (Product number SPP-751) was purchased from Assay Designs, 5777 Hines Drive, Ann Arbor, MI 48108, USA.
Antibodies a *a Antibodies having specificity for each of the proteins Hsp9O, Hsp7O, Hsc7O and I...
Clusterin were utilised in the experimental procedures. * **
*.::. Sperm atozoa-A PM and spermatozoa-Hsc 70 co-incubation a..
Swim-up spermatozoa fractions (50 x 106 spermatozoa/mI) in 25.il aliquots were added : * : :* to 25.tl of APM or Hsc7O protein (variable concentrations depending on experimental * 25 design). Spermatozoa-APM and spermatozoa-Hsc7O co-incubation droplets were covered with mineral oil, incubated at 39 deg. C., in an atmosphere containing 5% CO2 for 24 hrs. After co-incubation 50 j.d of PBS containing 20 itM SYBR-14 and 2 j.tM ETHD-1 was added to each droplet and further incubated for 15 mm. Thereafter the sperm viability was assessed as described above.
P2988RVC0803 I 8j Sperm viability assays Boar sperm viability in the presence of antibody-treated sAPM Antibody-treated sAPM (200 j.tg/mL) was prepared by incubating sAPM with antibodies for 2 hours on a rotary shaker at room temperature. A series of preliminary experiments was undertaken to determine approximately how much antibody was required to prevent binding of FITC-5 labelled sAPM to washed boar spermatozoa. For this purpose boar spermatozoa were incubated with antibody-treated sAPM. Antibodies to Hsc7O, Hsp7O and Hsp9O (Abcam Plc, Cambridge, UK) were supplied at 0.2 mg protein/mL and diluted in TLP (1:200 v/v). Semen from 8 boars was individually washed with Percoll-saline as previously described and each sample (in TALP) was adjusted to give a final concentration of 25 x 106 10 spermatozoa /mL. 15 i.iL droplets of sperm suspension and antibody-treated sAPM (with untreated sAPM and TLP as control treatments) were mixed 1:1 in 20 mm diameter wells in 4 well Multi-dish plates (Sigma Aldrich, Poole, Dorset, UK) and then covered with mineral oil. They were incubated at 39 C in 5% C02 for 24 hours. The viability of spermatozoa was assessed at zero hours and after 24 hours.
Dose response effect of Hsc7O protein on sperm viability Boar spermatozoa were prepared as previously described. Recombinant bovine Hsc7O * ** **.. (Stressgen, Ann Arbor, Mi, USA; SPP-75 1) was diluted in UP to give final **** concentrations of 8, 2, 0.5 and 0.25.tg/mL (series 1, Figure 4B) and 4, 0.5 and 0.1 * *. p.g/mL (series 2, Figure 4C) and when incubated with equal volumes of spermatozoa.
Control samples were incubated in UP only or TLP + sAPM (200 p.g/mL). The samples ** were incubated at 39 C in 5% Co2 for 24 hours. Sperm viability was examined as : * * described previously. ****
Effect of Hsc7O protein on bull sperm viability Serial dilutions of bovine recombinant Hsc7O and a control protein alpha tubulin were prepared in TALP to give final concentrations of 4, 1, 0.5 and 0.1.tg/mL (Figure 5).
Spermatozoa were added to droplets of TALP, TALP + alpha tubulin (Abcam plc, Cambridge, UK) or TALP + recombinant Hsc7O in equal volumes of 25 i.tL each. The 50 t.tL droplets were covered with mineral oil and incubated at 37 C in a 5% C02 incubator for 48 hours. The viability of samples was assessed at zero hours and then at 48 hours following the same procedure as that for boar spermatozoa.
P2988RVC0803 I 8j Effect of Hsc7O protein on ram sperm viability Freshly collected and washed ram spermatozoa were co-incubated for up to 48 h with seven different concentrations of bovine recombinant Hsc7O and without protein (Figures 6A-6C). The final concentrations of Hsc7O were: 16, 8, 4, 2, 1, 0.5, and 0.25 jig of protein/mi. The viability of the spermatozoa co-incubated with or without Hsc7O was determined at 24 h and 48 h. This experiment was replicated using spermatozoa from eight rams.
Microencapsulation of spermatozoa Suspensions of spermatozoa in physiological saline containing 1% sodium alginate (w/v), pH 6.8, were passed through a syringe pump to form droplets having a mean diameter of between 0.75 and 1.5 mm. Briefly, the spermatozoa suspension within a 10 ml syringe was forced through a 19 gauge hypodermic needle contained within an encapsulating jet at a rate of approximately 1.5 mi/mm to form droplets which were collected in a beaker containing aqueous solution (80 ml) of 1.5% CaC12-Hepes buffer (50 mM) pH 6.8. Immediately on contact with the CaCl2-Hepes buffer solution, the droplets absorb calcium ions, which cause solidification of the entire-cell suspension resulting in a shape-retaining, high viscosity microcapsule. To form a semi-permeable **. 20 membrane on the surface of the microcapsules, the microcapsules were rinsed three * * times with physiological saline and suspended in physiological saline containing 0.4% * polylysine having a molecular weight range of 25 to 50 kDa. The excess polylysine was *.
* aspirated and the microcapsules rinsed with 0.1% CHES buffer, pH 8.2. After three : * rinses with physiological saline, the alginate gel inside the microcapsules was liquefied *...: 25 by suspending the capsules in isotonic 3% sodium-citrate saline solution, pH 7.4 for approximately 5 minutes.
Cryopreservation of spermatozoa Collected semen was allowed to cool slowly to room temperature over a period of around 2 hours. Semen was aliquoted into tubes containing approximately 6 x 1 spermatozoa and centrifuged at room temperature for 10 minutes at 300 g. The supernatant was removed by aspiration and the spermatozoa resuspended into Beltsville F5 extender (5 ml).
P2988RVC0803 I 8j The tubes containing the extended spermatozoa were then placed in a beaker containing water (50 ml) at room temperature, which was then placed into a refrigerator and cooled to 5 deg. C. over a two hour period. After the spermatozoa were cooled, 5 ml of Beltsville F5 extender containing 2% glycerol was added to each tube. The contents of the tubes were mixed by immersion and frozen immediately into pellets of 0.15 ml to 0.2 ml on dry ice. The pellets were then transferred to liquid nitrogen for storage.
SILAC and parallel pury'Ication and analysis of individual cellular compartments Stable isotope Labelling with Amino acids in Cell culture (SILAC) combined with the parallel purification and analysis of individual cellular compartments (cell-surface and intracellular compartments) was employed to investigate protein trafficking in response to gamete presence in the oviduct. Oviductal epithelial cells (OEC) were cultured in a medium containing stable isotope labelled arginine to create an isotope labelled OEC population otherwise identical to an unlabelled OEC population. Both populations were co-incubated with spermatozoa for 6 hours. However spermatozoa were in direct physical contact with the labelled OEC, and separated from direct physical contact with unlabelled OEC by a diffusible membrane. Cell-surface proteins were then biotinylated, and affinity-purified using iminobilised avidin, to create a cell-surface' protein fraction. * .**
*....* 20 Non-biotinylated proteins were collected to create an intracellular' protein fraction.
: ** Proteins were separated by 1D gel electrophoresis, and subjected to Liquid * Chromatography/Mass Spectrometry/Mass Spectrometry (LC-MS/MS). a
* :" In vitro fertilization technique Sow ovaries were obtained from a local abattoir (A & G Barber, Purleigh, Essex, UK); these were placed in 0.9% saline solution supplemented with 100 IU/mL penicillin-G and 100 j.tg/mL streptomycin sulphate solution (pen/strep; Invitrogen Life Technologies, Paisley, UK) and maintained in a thermos flask at 25-30 C for transportation to the laboratory. On arrival the ovaries were washed in lukewarm water then rinsed in warm saline solution with pen/strep supplements.
Follicular fluid from 3-6 mm diameter ovarian follicles were aspirated using an 18.5 gauge needle attached to a I OmL disposable syringe containing 2mL of collection P2988RVC0803 1 8j medium 1 (TCM 199 supplemented with 5mM NaHCO3, 15mM Hepes (Na salt or free acid), 0.05g/L kanamycin sulphate, 0.4% (wlv) BSA fraction V and 0.04g/L heparin).
The aspirated fluid was then filtered through a 70 pm cell strainer to harvest the oocytes.
The oocytes were washed and collected into pre-warmed collection medium 2 (TCM 199 (with Hanic' s salts and sodium bicarbonate) supplemented with 0.1% (w/v) polyvinyl alcohol, 3.05mM D10 glucose, 0. 91mM sodium pyruvate and pen-strep solution).
Cumulus-oocyte complexes (COCs) were collected under a stereomicroscope; oocytes had at least two complete layers of cumulus cells and evenly granulated ooplasm. The selected COCs were washed in collection medium 2 and transferred in groups of 50 COCs into pre-equilibrated 500mL wells of IVM medium (1CM 199 (with Earle's salts, L-glutamine and sodium bicarbonate) and supplemented with 0.1% polyvinyl 5 alcohol, 3.05mM D-glucose, 0.91mM sodium pyruvate, 0.57iM cysteine and lOng/mL epidermal growth factor and pen-strep solution and pre-equilibrated). Before oocyte transfer 0.5p.g/mL LH and 0.5j.tg/mL FSH were added to the 500 pL maturation droplets. The preparations were incubated for 48h. After IVM incubation 0.1% (w/v) hyaluronidase was added for 30 mm to the maturation droplets to loosen the cumulus cells. COCs were then washed in pre-equilibrated mTBM (modified Tris-buffered medium (mTBM: *....* 113.1mM NaCI, 3mM KC1, 20mM Tris-base, 11mM D-glucose and 5mM sodium .... 20 pyruvate supplemented with 5mM NaHCO3 and 0.4% (w/v) BSA). After equilibration of : *. the medium, 10mM CaCI2 was added to avoid precipitation). Groups of 30-40 COCs * were placed in pre-equilibrated 98p.L droplets of mTBM covered in mineral oil.
Approximately 3 x 106 mL of Percoll-washed spermatozoa were incubated for 10 miii in : I mL of pre-equilibrated mTBM containing 1 tg/ mL recombinant Hsc7O or 50.Lg/mL * :.: 25 sAPM as appropriate. 2 j.tL sperm suspension were added to the WF droplets, to give a final concentration of 6 x 104 spermatozoa /mL. The oocytes and spermatozoa were co-incubated for 6 h. Following sperm-oocyte co-incubation, the presumptive zygotes were collected into I mL of preequilibrated NCSU23 medium (North Carolina State University-23 medium: 108.73mM NaCl, 4.78mM 20 KCI, 1.19mM K2P04, 1.19mM MgSO4.7H20, 1mM L-glutamine, 5.55mM D-glucose, 7mM taurine, 5mM hypotaurine, 25.07mM NaHCO3 and 1.71mM CaCl2 supplemented with 0.4% (w/v) BSA and pen-strep solution) in a 5 mL P2988RVC0803 I 8j glass tube and vortexed for 2 mm to remove loosely bound spermatozoa and cumulus cells. The presumptive zygotes were then washed twice in fresh pre-equilibrated 40 pL droplets of NCSU23 and transferred to 20 p.L of the same medium in groups of 20-25.
They were cultured for 48h and then fixed in 2.5% paraformaldehyde fixative with 0.5% triton X-100 for 30 mm at 39 C. The embiyos were washed (x 3) in warm PBS and stained with 10 jig/mL P1 for 10 mm before being mounted in mounting medium (Vectashield, Vector Laboratories). They were examined by confocal microscopy (Zeiss LSM 510, Germany) to identify fertilisation status. The oocytes/embryos 5 were classified as (1) unfertilised oocytes (the presence of metaphase plates or female pronuclei), (2) fertilised, with male and female pronuclei, (3) one cell embryos, (4) cleaved embryos with two or more cells (5) embryos with more than 4 cells.
Statistical Analysis The data were expressed as mean viability index SEM. Viability index was defined as percentage of viable spermatozoa after 24 hours incubation in comparison to that of the initial viability of the same semen sample at the beginning of incubation period. Sperm viability data were tested for normal distribution. Analysis of variance was used for the statistical analysis of the data. The level of significance was considered P = 0.05. * ** * . 0 * e. **.* * * *.Oe
* ** Results *0 S S...
* Labelling and detection of sA PM proteins *.
The inventors have previously shown that incubating boar spermatozoa with sAPM * : :* proteins from sow oviducts enhances the viability of the spermatozoa. In US * : * 25 2004/0086 842, the inventors have also previously demonstrated the transfer of several labelled sAPM proteins to spermatozoa protein profiles. Since the labelling of the sAPM proteins was performed after purification and solubilisation, it was conceivable that the labelled protein fraction may not be exclusively surface proteins, meaning that their biological relevance was questionable.
The inventors therefore devised a method to distinguish surface-located proteins of oviductal origin based on the biotin/avidin interaction (Holt et al., 2005), as described P2988Rvc0803 I 8j previously. Labelled protein bands on the blots were seen in the spermatozoa protein profiles. These were most likely to be oviductal proteins.
Identification of candidate sAPM proteins using proteomic analysis S Further samples of spermatozoalsAPM were separated by SDS-PAGE and the proteins stained within the gels. Proteins in four of these excised bands were subjected to proteomic analysis as described previously. Approximately 30 proteins were identified by the use of bioinformatic analysis, and of these, 19 were selected for further investigation based on their species specificity, tissue specificity, and putative or known activity. This selection of 19 was logically reduced by further bioinforrnatic analysis to 4 proteins (Hsp9O, Hsp7O, Hsc7O and Clusterin), all of which belong to the heat shock protein family.
Identification of Hsc 70 as a sA PM protein having sperm viability improving properties Having narrowed the activity of the sAPM fraction to four proteins, further investigation was then undertaken to determine which protein was responsible for the improved viability of spermatozoa. Commercial antibodies having specificity for each of the proteins Hsp9O, 1-lsp7O, Hsc7O and Clusterin were purchased. Bioassays of boar sperm * .S * ** survival were performed as detailed above, whereby the respective antibodies were *.* 20 included within the media in order to neutralise specific protein functions of the sAPM fraction. * * .
Figure 1 shows the viability index (Mean SEM) of boar spermatozoa incubated with different concentrations of antibodies.
Column 1: No antibody, no treatment with sAPM fraction Column 2: sAPM fraction, showing increase in sperm viability Column 3: sAPM fraction and anti-Hsp7O antibody Column 4: sAPM fraction and anti-Hsc7O antibody Column 5: anti-Hsp7O antibody in Tyrode's TALP medium Column 6: anti- Hsp7O antibody in Tyrode's TALP medium.
Viability index is the percentage of viable spermatozoa after 24 hours incubation in comparison to that of the initial viability of the same semen sample at the beginning of incubation period. The greatest effect was obtained with the anti-Hsc7O antibody P2988RVC0803 1 8j (column 4), where the viability enhancement effect of sAPM was significantly reduced (P=0.00057).
When the 24 h bioassays were repeated using sAPM and antibody-treated sAPM, it was found that the beneficial effect of sAPM on sperm survival was negated only by the action of anti-Hsc7O (P = 0.013; Fig. 4A) . Antibodies against Hsp7O and Hsp9O did not reduce the sAPM effect and there was no deleterious effect on spermatozoa of anti-Hsc7O antibody treatment alone (P>0.05). This outcome indicated that Hsc7O was a particularly interesting protein worthy of further investigation.
Characterization of Hsc 70 and sperm viability Co-incubation studies were undertaken to investigate the effect of HsclO on sperm viability, by utilising various concentrations of the recombinant Hsc7O protein. These data are shown in Figures 2, 4B, 4C and 5. As shown in Figure 2, bovine Hsc7O protein was effective with boar spermatozoa at concentrations between 2-1 6ig/ml.
The other three proteins investigated in parallel with HsclO did not confer any protection to boar spermatozoa (see Figure 1). Combinations of Hsc7O and the other proteins also * *S failed to provide enhanced sperm survival and even caused deleterious changes. a.. * I I...
-.. incubation of boar spermatozoa with the Hsc7O protein instead of sAPM showed improved viability over the control (TALP medium only) after 24h incubation (as shown ** in Figure 3).
I * I * IS.'
To test the effects of Hsc7O itself on boar sperm survival at 39 C under capacitating conditions, washed spermatozoa were incubated in TLP containing 0, 2, 4, 8 and 16 jig/mL Hsc7O for 24h and then evaluated for plasma membrane integrity (data not shown). There was a significant overall enhancement of sperm survival, represented by a 15% increase in viability index, due to the presence of Hsc7O (P=O.007). However, this beneficial effect'appeared to be optimal at 2 jtg/mL (P0.0007; F1/24 = 14.9) and there was no further benefit to be gained by further increasing the concentration of protein.
P2988RVC0803 I 8j This outcome was pursued further by repeating the bioassays, but using lower concentrations of l-lsc7O (0, 0.25, 0.5, 2 and 8 p.g/mL -see Figure 4B). As an additional comparison, the spermatozoa were also incubated in the presence of 200 g/mL sAPM to evaluate the effectiveness of Hsc7O against the original oviductal preparation. The beneficial effects of Hsc7O were evident at both 0.25 and 0.5 jg/mL (P = 0.034 for the comparison between TLP and 0.25 j.tg/mL and P<0.00l for the specific comparison between TLP and both concentrations together). Both of the higher concentrations (2 and 8 jtg/mL) were less effective at maintaining sperm survival and it was concluded that the optimal concentration must be lower than 2 jtg/mL. I0
A further series of bioassays was therefore undertaken using an even lower range of Hsc7O concentrations (0.1, 0.5, 1 and 4 j.tg/mL -see Figure 4C). As before, sAPM (200 .tg/mL) treatment was also included. Beneficial effects on sperm survival over a 24 b period were evident with Hsc7O at 0.1 j.tg/mL (P = 0.005), 0.5 j.ig/mL (P = 0.0001) and I ig/mL(P=0.000l).
Effects ofHsc7O on spermatozoa from other species As Hsc7O is so highly conserved (see below, and alignment in Figure 7) the inventors * *5 **. hypothesized that its role in sperm viability maintenance should apply to mammals other **.* .... 20 than the pig. To test this hypothesis sperm viability experiments were set up using bull or : ** ram spermatozoa, instead of boar spermatozoa. ** As.
When buil spermatozoa were incubated in the presence of Hsc7O for 48h at 37 C under : :: capacitation conditions, approximately 50% remained viable. However, the inclusion of *:" 25 Hsc7O in the TLP medium increased the rate of sperm survival in a dose dependent manner up to an optimal value at lig/mL (TLP control v l.tg/mL Hsc7O; P=0.0013).
Although increasing the dose of Hsc7O further (to 4p.g/mL) still resulted in a beneficial effect on sperm survival (P=0.006) compared to TLP alone, the higher dose was less effective at maintaining sperm survival. When spermatozoa were incubated in media containing tubulin as a control protein treatment, there was no significant difference in outcome with respect to the TLP control. These results are summarised in Figure 5.
P2988RVC0803 1 8j Ram spermatozoa co-incubated with Hsc7O for 48h were more viable than those in medium without protein (F11112 = 3.92; P = 0.05; Figure 6A). Although intermediate (1-2 p.g of protein/mi) concentrations of Hsc7O maintained ram sperm viability significant'y (F11 = 4.74; P < 0.04) better than medium without protein, the optimal concentration of Hsc7O for maintaining sperm viability was 4 j.tg of protein/mi (F11 = 5.67; P <0.03) (Figure 6B). Lower (0.25-0.5 p.g of protein/mi) and higher (8-16.tg of protein/mi) concentrations of Hsc7O did not maintain sperm viability significantly better than medium without protein. A significant log-linear relationship (F1148 = 10.61; P <0.003) was observed between sperm viability and HSc7O dose over the low to intermediate protein concentrations (0.25-4 jig of protein/mi; Figure 6C).
In summary Hsc7O prolongs ram sperm survival significantly better than the control (TLP+BSA medium without Hsc7O) over a 48 h in vitro co-incubation period. These results are consistent with those found with boar and bull spermatozoa.
In vitro fertilization assays Spermatozoa were briefly (10 mm) exposed to 1 p.g/mL of recombinant bovine Hsc7O S...
protein before being diluted (1: 200) into the final fertilisation droplet. A control treatment with no protein exposure was also set up. The summarised IVF results are 20 shown in Table I. Table 1: Effect of exposing sperinalozoa to Hsc 70 protein for 10 minutes prior to transfer into
S
* * the IVF droplet.
Treatment No. Degenerate Failed Fertilised Monospermic 2PN stage 3 or 4 cell 7/8 cell oocytes oocy*es to (%) (%) or later (% embryos or embryos fertilize of later (% of or later fertilized) fertilized) (% of fertilized) Control 72 26 17 29(40.3) 17(58.6) 16 (55.1) 11(37.9) 1(35) Hsc7O 72 35 10 27(37.5) 24(88.9) 27(100) 20(74.1) 6(22.2) Total 144 6! 27 56 41 43 31 7 a Significantly higher than the corresponding control value (P < 0.05).
* Significantly higher than the corresponding control value (P < 0.05).
Exposure to Hsc7O did not enhance the fertilization rate compared to the control, but it significantly reduced the extent of polyspermy (control v Hsc7O; 41.4% v 11.1%; P < P2988RVC0803 18j 0.05). Exposing spermatozoa to Hsc7O also appeared to increase the rate of embryonic development so that by 60 hours of incubation a higher proportion of embryos had reached or passed the 3 or 4 cell stage (control v Hsc7O; 41.4% v 96.3%: P< 0.05).
Hsc7O prolongs and maintains the viability of spermatozoa from other species Further experiments (described above) using ram and bull spermatozoa and bovine Hsc7O have confirmed that the protein is also effective at prolonging the viability of spermatozoa within sheep and ox (cattle). The protein enhanced survival at 48h, and proved effective and dose-dependent at lower doses than in the pig (in the range 0.5 -4 jig/ml). In addition to the effect with boar, bull and ram spermatozoa, a porcine APM fraction has been shown to improve and/or prolong the viability of elephant spermatozoa (data not shown). There is therefore good evidence to suggest that the effect of the protein is exerted across a wide range of species, most likely due to the very high degree of conservation exhibited between members of the Hsc7O family (see below, and Figure 7). * ** * . a * *.
* Hsc7O is a major protein constituent of sAPM * Western blots of sAPM from both pig and sheep have confirmed that Hsc7O is a major protein constituent of sAPM (data not shown). a..
: *** Conservation of Hsc 70 across species The ClustalW algorithm (Higgins et a!.) (http://www.ebi.ac.uklclustalwl) was utilised to align 33 Hsc7O protein sequences to determine their protein identity. ClustaiW is a general purpose multiple sequence alignment program which produces biologically meaningful multiple sequence alignments of divergent sequences. Pairwise scores are calculated as the number of identities in the best alignment divided by the number of residues compared (gap positions are excluded).
The scores table from the ClustalW alignment is shown in Figure 7. The table compares a first named sequence (SeqA) against a second named sequence (SeqB). The length (in amino acid residues) is listed for each of SeqA and SeqB. As can be seen from the table, Hsc7O is very highly conserved between species. Taking the bovine protein as an example (seqA 15), this protein shares 99% identity with human, orang-utan, Chinese hamster, and rat Hsc7O, 97% identity with chicken Hsc7O, and 94-95% identity with P2988RVC0803 1 Sj zebrafish Hsc7O, and 92% identity with Xenopus Hsc7O. The very high degree of identity between species is further evidence that Hsc7O protein from one species could be utilised to prolong/improve/maintain sperm viability from another species.
Hsc7O expression in the sAPM is increased in response to the presence of spermatozoa in the oviduct The interaction between Hsc7O andspermatozoa has been validated through further experimentation to investigate gene expression and protein secretion in response to gamete presence in the oviduct. I0
In nearly all biological systems, eukaryotic cells regulate the abundance and distribution of cell-surface proteins in response to contact with an adjacent cell. The export and internalisation of whole receptor molecules after ligand binding is a well characterised phenomenon. Surface protein trafficking from and towards internal cellular compartments can not be identified using gene expression technologies. These changes * :*: are not necessarily the result of changes in gene expression and protein production, but rather the result of protein dynamics and interactions. The present inventors developed a : technique for investigating global cell-surface protein trafficking (rather than just investigating specific protein trafficking). The methodology utilised SILAC combined *.* with the parallel purification and analysis of individual cellular compartments (cell- : * surface and intracellular compartments). Approximately 30% of identified proteins were S...
quantified according to the relative abundance of labelled compared to unlabelled MS spectra. Direct contact of spermatozoa with oviductal epithelial cells (OEC) altered the abundance of Hsc7O on the OEC cell surface, while the presence in the intracellular compartment did not show any change. This suggests that the alteration of the protein was not due to a change in protein synthesis, but rather, the result of its transport to the cell surface.
Conclusions
From these data the present inventors conclude that the principal protein responsible for the protective action of sAPM with spermatozoa is Hsc7O, and that Hsc7O expression on the surface of oviductal epithelial cells is modulated through contact of the cell with spermatozoa.
P2988RVC0803 1 8j
Summary
The inventors have identified Hsc7O as a protein present with the sAPM of oviductal epithelial cells which can maintain and prolong the viability of spermatozoa. These data show an important role for Hsc7O in the maintenance of sperm survival in vitro and imply that the mechanism of action should be highly conserved across species. The experiments demonstrating that recombinant bovine FIsc7O was beneficial to bull and ram, as well as boar spermatozoa in vitro indicates that this highly conserved protein could be a useful additive to sperm extenders used for artificial insemination. Inter-species variability in effectiveness is a major difficulty for the development of sperm extenders in mammals, but the present inventors believe that such a highly conserved protein as Hsc7O may be useful in overcoming this problem.
The present invention provides an effective diluent additive which enables A! centre * ** operators to extend the shelf-life of diluted semen beyond the timeframe currently guaranteed, which is for example 3-5 days for boar semen. Further, the present invention enables cryopreservation of semen without loss of fertility. In addition, the present : .. invention enables increased dilution of semen without loss of fertility and further the **.* *. 20 present invention provides a means of increasing fertility. The present invention also provides means for sperm viability to be higher following cryopreservation, thus enabling efficient freezing and subsequent provision of high numbers of viable * : : spermatozoa following freezing.
References Smith, U, and Nothnick, WB. Role of direct contact between spermatozoa and oviductal epithelial cells in maintaining rabbit sperm viability. Biology of Reproduction 1997; 56:83-89.
P2988RVC0803 1 8j Satake N, Aihaider AK, Holt WV, and Watson PF. Exposure of spermatozoa to solubilised extracts of the oviductal ep it helium apical plasma membrane enhances fertilisation in porcine IVF. Abstract presented at 33rd Annual Conference of the International Embryo Transfer Society, Kyoto, Japan, January 7-9, 2007.
Laemmli UK. Cleavage of Structural proteins during the assembly of the head of bateriophage T4. Nature 1970: 227, 689.
Holt WV, Elliott Rivi, Fazeli A, Satake N, Watson PF. Validation of an experimental strategy for studying surface-exposed proteins involved in porcine sperm-oviduct contact interactions. Reprod Fertil Dev. 2005; 1 7(7):683-92.
Higgins U., Thompson J, Gibson T. Thompson J D, Higgins DG, Gibson TJ.
CLUSTAL W: improving the sensitivity ofprogressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res. 1994:.22, 4673-4680. * a * ** * * * **.. a I.. * ** * * I * III
I
I..... * *
P2988RVC0803 I 8j
SEQUENCE LISTING
<110> The Royal Veterinary College <120> Method for enhancing sperm survival <130> P2988 <160> 1 <170> Patentln version 3.3 <210> 1 <211> 650 <212> PRT <213> Bos taurus <400> 1 Met Ser Lys Gly Pro Ala Val Gly lie Asp Leu Gly Thr Thr Tyr Ser 1 5 10 15 Cys Val Gly Val Phe Gin His Gly Lys Val Glu lie lie Ala Asn Asp 25 30 *i'. Gin Giy Asn Arg Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Giu S 35 40 45 S... * . S...
* ** Arg Leu lie Gly Asp Ala Ma Lys Asn Gin Val Ala Met Asn Pro Thr * S S S... * S..
S
Asn Thr Val Phe Asp Ala Lys Arg Leu lie Gly Arg Arg Phe Asp Asp * .. 65 70 75 80 * S * S...
S
S.....
* * Ala Val Val Gin Ser Asp Met Lys His Trp Pro Phe Met Val Val Asn 90 95 Asp Ala Giy Arg Pro Lys Vai Gin Val Glu Tyr Lys Gly Glu Thr Lys 105 110 Ser Phe Tyr Pro Glu Glu Val Ser Ser Met Val Leu Thr Lys Met Lys 120 125 Giu lie Ala Glu Ala Tyr Leu Gly Lys Thr Val Thr Asn Ala Val Val 135 140 Thr Val Pro Ala Tyr Phe Asn Asp Ser Gin Arg Gin Ala Thr Lys Asp 150 155 160 Ala Gly rhr lie Ala Gly Leu Asni Val Leu Arg lie lie Asn Glu Pro 170 175 P2988RVC0803 I 8j 3) Thr Ala Ala Ala lIe Ala Tyr Gly Leu Asp Lys Lys Val Gly Ala Giu 185 190 Arg Asn Val Leu lie Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser 200 205 lie Leu Thr lie Glu Asp Gly lie Phe Glu Val Lys Ser Thr Ala Giy 210 215 220 Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg Met Val Asn His 225 230 235 240 Phe Ile Ala Glu Phe Lys Arg Lys His Lys Lys Asp lie Ser Glu Asn 245 250 255 Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Giu Arg Ala Lys Arg 260 265 270 Thr Leu Ser Ser Ser Thr Gin Ala Ser lie Glu lie Asp Ser Leu Tyr 275 280 285 * I* S... * S I.'.
Glu Gly lie Asp Phe Tyr Thr Ser lie Thr Arg Ala Arg Phe Glu Glu * , 290 295 300 * S S...
Leu Asn Ala Asp Leu Phe Arg Gly Thr Leu Asp Pro Vai Giu Lys Ala 305 310 315 320 * S. S. * S...
: Leu Arg Asp Aia Lys Leu Asp Lys Ser Gin lie His Asp lie Val Leu * 325 330 335 Val Gly Gly Ser Thr Arg lie Pro Lys lie Gin Lys Leu Leu Gin Asp 340 345 350 Phe Phe Asn Gly Lys Glu Leu Asn Lys Ser lie Asn Pro Asp Glu Ala 355 360 365 Val Ala Tyr Giy Ala Aia Val Gin Ala Ala lie Leu Ser Gly Asp Lys 370 375 380 Ser Glu Asn Val Gin Asp Leu Leu Leu Leu Asp Vai Thr Pro Leu Ser 385 390 395 400 Leu Gly lie Giu Thr Ala Gly Gly Val Met Thr Vai Leu lie Lys Arg 405 410 415 P2988RVC0803 1 8j Asn Thr Thr lie Pro Thr Lys Gin Thr Gin Thr Phe Thr Thr Tyr Ser 420 425 430 Asp Asn Gin Pro Gly Val Leu lie Gin Vai Tyr Glu Giy Glu Arg Ala 435 440 445 Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe Glu Leu Thr Giy lie 450 455 460 Pro Pro Ala Pro Arg Gly Val Pro Gin lie Glu Val Thr Phe Asp lie 465 470 475 480 Asp Ala Asn Gly lie Leu Asn Val Ser Ala Val Asp Lys Ser Thr Gly 485 490 495 Lys Glu Asn Lys lie Thr lie Thr Asn Asp Lys Gly Arg Leu Ser Lys 500 505 510 Glu Asp lie Giu Arg Met Vai Gin Glu Ala Giu Lys Tyr Lys Ala Glu 515 520 525 * S. *. S * *. *..,
Asp Glu Lys Gin Arg Asp Lys Vai Ser Ser Lys Asn Ser Leu Lys Ser 530 535 540 * S. * . S **** * Tyr Aia Phe Asn Met Lys Ala Thr Vai Glu Asp Giu Lys Leu Gin Gly 545 550 555 560 * S. * . S a... Lys lie Asn Asp Glu Asp Lys Gin Lys lie Leu Asp Lys Cys Asn Glu : 565 570 575 * q lie lie Asn Trp Leu Asp Lys Asn Gin Thr Ala Glu Lys Glu Glu Phe 580 585 590 Glu Ills Gin Gin Lys Glu Leu Glu Lys Val Cys Asn Pro lie lie Thr 595 600 605 Lys Leu Tyr Gin Ser Ala Gly Gly Met Pro Gly Giy Met Pro Gly Gly 610 615 620 Met Pro Gly Gly Phe Pro Giy Giy Gly Ala Pro Pro Ser Gly Gly Ala 625 630 635 640 Ser Ser Giy Pro Thr lie Giu Glu Va! Asp 645 650 P2988RVC0803 I 8j
Claims (36)
- Claims 1. A spermatozoa diluent comprising isolated Hsc7O protein, inwhich the Hsc7O has sperm viability improving and/or prolonging activity.
- 2. A spermatozoa diluent as claimed in any preceding claim wherein the concentration of the Hsc7O protein is between approximately 0.1 j.tg/L and 10 g/L.
- 3. A spermatozoa diluent comprising Hsc7O protein, in which the Hsc7O has sperm viability improving and/or prolonging activity, wherein the concentration of the Hsc7O protein is between approximately 0.1 j. tg/L and 10 g/L.
- 4. A spermatozoa diluent as claimed in any preceding claim in which the Hsc7O protein is selected from the group consisting of: human, pig, sheep, ox, camel, horse, dog, cat, poultry, rabbit, buffalo, elephant, llama, guanaco, alpaca, and vicuna.
- 5. A spermatozoa diluent as claimed in any preceding claim wherein the Hsc7O is a *: :: : protein comprising the sequence of SEQ ID NO: 1. * **
- 6. A spermatozoa diluent as claimed in any one of claims 1-4, wherein the Hsc7O *.I * 20 protein has at least 80% identity with the protein listed in SEQ ID NO. 1, or at least 85%, : * ** at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least * *e.99.5% or at least 99.9% identity with the protein listed in SEQ ID NO. 1.
- 7. A spermatozoa diluent as claimed in any preceding claim wherein the diluent comprises at least one of glucose, sodium citrate dihydrate, EDTA, sodium bicarbonate, potassium chloride, and water.
- 8. A spermatozoa diluent as claimed in any preceding claim wherein the Hsc7O protein is linked to an inert polymer.
- 9. A spermatozoa diluent as claimed in claim 8 wherein the polymer is hydrophilic.P2988RVC0803 I 8j l4
- 10. A spermatozoa diluent as claimed in claim 9 wherein the polymer is amine and carbonyl-reactive dextran.
- 11. A spermatozoa diluent as claimed in any preceding claim further comprising spermatozoa.
- 12. A spermatozoa diluent as claimed in claim II wherein the spermatozoa are selected from the group consisting of: human, pig, sheep, ox, camel, horse, dog, cat, poultry, rabbit, buffalo, elephant, llama, guanaco, alpaca, and vicuna.
- 13. A spermatozoa diluent as claimed in claim 11 or claim 12, wherein the spermatozoa are microencapsulated.
- 14. A spermatozoa diluent as claimed in claim 13 wherein the spermatozoa are microencapsulated in a semi-permeable membrane. * ** * . * *.
- 15. A spermatozoa diluent as claimed in claim 14, wherein the semi-permeable : membrane comprises poly-lysine. S..* 20
- 16. A spermatozoa diluent as claimed in claim 13 wherein the spermatozoa are : .. microencapsulated in sodium alginate gel.**.*..*
- 17. A kit of parts comprising the diluent of claims 1-10, and spermatozoa.
- 18. Use of a spermatozoa diluent as claimed in any one of claims 1-16 to improve and/or prolong sperm viability in vitro.
- 19. Use of Hsc7O protein to improve and/or prolong sperm viability in vitro.
- 20. Use of Hsc7O protein in the manufacture of a medicainent to improve and/or prolong sperm viability.P2988RVC0803 1 8j
- 21. The use of Hsc7O protein as claimed in claim 19 or claim 20 wherein the Hsc7O protein is selected from the group consisting of: human, pig, sheep, ox, camel, horse, dog, cat, poultry, rabbit, buffalo, elephant, Llama, Guanaco, Alpaca, and Vicuna.
- 22. The use of HsclO protein as claimed in claim 19 or claim 20, wherein the Hsc7O is a protein comprising the sequence of SEQ ID NO: 1.
- 23. The use of Hsc7O protein as claimed in any one of claims 18-20, wherein the Hsc7O protein has at least 80% identity with the protein listed in SEQ ID NO. 1, or at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% or at least 99.9% identity with the protein listed in SEQ ID NO. 1.
- 24. The use of Hsc7O protein as claimed in claims 18-23 wherein Hsc7O is linked to an inert polymer.
- 25. The use of Hsc7O protein as claimed in claim 24 wherein the polymer is S...* * hydrophilic. * *.. * S.
- 26. The use of Hsc7O protein as claimed in claim 24 wherein the polymer is amine * 20 and carbonyl-reactive dextran. * S. * . . *.S.* : ..:
- 27. A method of improving andlor prolonging sperm viability which comprises contacting spermatozoa with HsclO.
- 28. A method as claimed in claim 27, wherein the spermatozoa are chilled, frozen or at ambient temperature or body temperature.
- 29. A method as claimed in claim 27 or claim 28, wherein the Hsc7O is provided in a diluent as claimed in any one of claims 1-10.P2988RVC0803 I 8j
- 30. A method as claimed in any one of claims 27-29, the method being carried out in vitro.
- 31. A method as claimed in any one of claims 27-30, the Hsc7O and spermatozoa being contacted for between about 30 seconds and 14 days.
- 32. A method as claimed in any one of claims 27-31, wherein the spermatozoa are cryopreserved prior to contact with Hsc7O.
- 33. A method as claimed in any one of claims 27-31, wherein the spermatozoa are contacted with Hsc7O during cryopreservation.
- 34. A method as claimed in any one of claims 27-32, wherein the method is performed during in vitro fertilisation.
- 35. A method as claimed in any one of claims 27-34 wherein the method is carried out before or after sex-sorting of the spermatozoa for X-(female) and Y-bearing (male) * ** spermatozoa. *. * **** ***
- 36. A method as claimed in any one of claims 27-29, the method being carried out in : *. vivo. *****.***I * * P2988RVC0803 I 8j
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0705626.0A GB0705626D0 (en) | 2007-03-23 | 2007-03-23 | Method for enhancing sperm survival |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0805134D0 GB0805134D0 (en) | 2008-04-23 |
GB2450770A true GB2450770A (en) | 2009-01-07 |
Family
ID=38024728
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0705626.0A Ceased GB0705626D0 (en) | 2007-03-23 | 2007-03-23 | Method for enhancing sperm survival |
GB0805134A Withdrawn GB2450770A (en) | 2007-03-23 | 2008-03-19 | Method for enhancing sperm survival using Hsc70 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0705626.0A Ceased GB0705626D0 (en) | 2007-03-23 | 2007-03-23 | Method for enhancing sperm survival |
Country Status (2)
Country | Link |
---|---|
GB (2) | GB0705626D0 (en) |
WO (1) | WO2008117026A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2659904T3 (en) | 2008-06-26 | 2016-01-29 | Orphazyme Aps | Use of Hsp70 as a regulator of enzymatic activity |
PL2646044T3 (en) | 2010-11-30 | 2020-03-31 | Orphazyme A/S | Methods for increasing intracellular activity of hsp70 |
ES2402505B1 (en) * | 2011-10-06 | 2014-03-12 | Universidad De Extremadura | DILUENT FOR FREEZING EQUINE SEMEN, PREPARATION METHOD AND APPLICATIONS |
CN102972350B (en) * | 2012-12-25 | 2014-01-29 | 黑龙江八一农垦大学 | Method for predicting fertility of ganders |
CN103766325B (en) * | 2014-01-02 | 2017-01-18 | 甘肃省畜牧兽医研究所 | Preparation and use methods for EG (ethylene glycol) and TCM199 serving as bovine semen diluent and bovine semen freezing liquid |
CN103704203B (en) * | 2014-01-03 | 2017-01-18 | 甘肃省畜牧兽医研究所 | Preparation method and using method for GL and TCM199 serving as bovine semen diluent and bovine semen refrigerating fluid |
WO2015193265A1 (en) | 2014-06-16 | 2015-12-23 | Università degli Studi di Parma | Composition for extenders for the long-term conservation of animal seminal material |
EP3922242A1 (en) | 2014-09-15 | 2021-12-15 | Orphazyme A/S | Arimoclomol formulation |
US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
EP3782624A1 (en) | 2016-04-29 | 2021-02-24 | Orphazyme A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
CN107212945A (en) * | 2017-06-20 | 2017-09-29 | 金寨县胜华娃娃鱼开发有限公司 | Preparation and application for the high-efficiency agent for dilution liquid of giant salamander seminal fluid |
CN107232184B (en) * | 2017-07-26 | 2021-02-05 | 西北农林科技大学 | Diluent for preserving semen of black pig in Guanzhong at normal temperature |
EP4247792A1 (en) | 2020-11-19 | 2023-09-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
CN113615682B (en) * | 2021-09-05 | 2022-08-26 | 内蒙古赛诺种羊科技有限公司 | Sheep hypertonic complexing agent semen dilution preserving fluid and application method thereof |
CN114794086A (en) * | 2022-06-08 | 2022-07-29 | 杭州东源生物科技有限公司 | Anti-coagulation pig semen dilution powder and application thereof |
CN116210678A (en) * | 2023-02-23 | 2023-06-06 | 安徽农业大学 | Normal temperature preserving preparation for pig semen and its use method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035560A1 (en) * | 2003-10-14 | 2005-04-21 | Universite Laval | Sperm protective polypeptides and uses thereof |
WO2007077560A2 (en) * | 2006-01-04 | 2007-07-12 | Do-Coop Technologies Ltd. | Cryoprotective compositions and methods of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE430161T1 (en) * | 2000-09-13 | 2009-05-15 | Multimmune Gmbh | PEPTIDE FROM HSP70 WHICH STIMULATES NK CELL ACTIVITY AND ITS USE |
AU2002313559A1 (en) * | 2001-08-23 | 2003-03-10 | Oxford Biomedica (Uk) Limited | Genes |
US20040086842A1 (en) * | 2002-10-31 | 2004-05-06 | Holt William Vincent | Factors for enhancement of sperm survival |
US7070918B2 (en) * | 2002-10-31 | 2006-07-04 | William Vincent Holt | Method for enhancement of sperm survival using soluble peripheral protein fraction of APM |
WO2004061458A2 (en) * | 2003-01-03 | 2004-07-22 | Aurelium Biopharma Inc. | Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
-
2007
- 2007-03-23 GB GBGB0705626.0A patent/GB0705626D0/en not_active Ceased
-
2008
- 2008-03-19 GB GB0805134A patent/GB2450770A/en not_active Withdrawn
- 2008-03-19 WO PCT/GB2008/000975 patent/WO2008117026A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035560A1 (en) * | 2003-10-14 | 2005-04-21 | Universite Laval | Sperm protective polypeptides and uses thereof |
WO2007077560A2 (en) * | 2006-01-04 | 2007-07-12 | Do-Coop Technologies Ltd. | Cryoprotective compositions and methods of using same |
Non-Patent Citations (1)
Title |
---|
Repro.Fert.Dev. Vol.20 No.1, 2008. Lloyd et al. "Heat shock cognate 70 protein improves the long-term survival of ram spermatozoa during storage at 17 degrees C in a commercial extender." p.88 * |
Also Published As
Publication number | Publication date |
---|---|
GB0705626D0 (en) | 2007-05-02 |
GB0805134D0 (en) | 2008-04-23 |
WO2008117026A1 (en) | 2008-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2450770A (en) | Method for enhancing sperm survival using Hsc70 | |
Rath et al. | In vitro fertilization of porcine oocytes with fresh and frozen-thawed ejaculated or frozen-thawed epididymal semen obtained from identical boars | |
Kątska-Książkiewicz et al. | Effects of oocyte quality, semen donor and embryo co-culture system on the efficiency of blastocyst production in goats | |
Avilés et al. | The oviduct A key organ for the success of early reproductive events | |
Al-Essawe et al. | Seminal plasma influences the fertilizing potential of cryopreserved stallion sperm | |
Zhang et al. | Extracorporeal development and ultrarapid freezing of human fetal ova | |
Al‐Katanani et al. | Induced thermotolerance in bovine two‐cell embryos and the role of heat shock protein 70 in embryonic development | |
Lloyd et al. | Effects of oviductal proteins, including heat shock 70 kDa protein 8, on survival of ram spermatozoa over 48 h in vitro | |
Davachi et al. | The effect of conspecific ampulla oviductal epithelial cells during in vitro maturation on oocyte developmental competence and maturation-promoting factor (MPF) activity in sheep | |
Tipkantha et al. | Influence of living status (single vs. paired) and centrifugation with colloids on the sperm morphology and functionality in the clouded leopard (Neofelis nebulosa) | |
Arruda et al. | Aspects related to the technique and the utilization of sexed semen in vivo and in vitro | |
Goudet et al. | Establishment of conditions for ovum pick up and IVM of jennies oocytes toward the setting up of efficient IVF and in vitro embryos culture procedures in donkey (Equus asinus) | |
Karja et al. | Effect of protein supplementation on development to the hatching and hatched blastocyst stages of cat IVF embryos | |
Shirazi et al. | In vitro developmental competence of ICSI-derived activated ovine embryos | |
Douet et al. | Exposure to follicular fluid during oocyte maturation and oviductal fluid during post-maturation does not improve in vitro embryo production in the horse | |
Davachi et al. | Effects of co-incubation with conspecific ampulla oviductal epithelial cells and media composition on cryotolerance and developmental competence of in vitro matured sheep oocytes | |
Deleuze et al. | Ovum pick up and in vitro maturation of jennies oocytes toward the setting up of efficient in vitro fertilization and in vitro embryos culture procedures in donkey (Equus asinus) | |
Zhou et al. | Effect of extenders and temperatures on sperm viability and fertilizing capacity of Harbin white boar semen during long-term liquid storage | |
KR100715188B1 (en) | Medium composition for in vitro culture of bovine embryo and culture method using the same medium | |
Cavusoglu et al. | Ultra‐structural alterations in in vitro produced four‐cell bovine embryos following controlled slow freezing or vitrification | |
Opiela et al. | Varied approach of using MSCs for bovine embryo in vitro culture | |
Huntress et al. | Pronucleus formation following in vitro fertilization of oocytes recovered from a gorilla (Gorilla gorilla gorilla) with unilateral endometrioid adenocarcinoma of the ovary | |
Opiela et al. | Varied approach of using MSCs for bovine embryo in vitro culture | |
Sato et al. | Prolonged survival of mouse epididymal spermatozoa stored at room temperature | |
EP3598895A1 (en) | An in vitro method for freezing mammalian embryos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |